Profil
Donald C.
Fresne served as the Chairman, President, and Chief Executive Officer of Epigen, Inc. from 1991 to 2010.
He also served as the President and Chief Executive Officer of Egenix, Inc. from 2012 to 2014.
Anciens postes connus de Donald C. Fresne
| Sociétés | Poste | Fin |
|---|---|---|
Egenix, Inc.
 Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Directeur Général | 19/12/2014 |
Epigen, Inc.
 Epigen, Inc. Medical SpecialtiesHealth Technology Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991. | Président | 23/09/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Epigen, Inc.
Epigen, Inc. Medical SpecialtiesHealth Technology Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991. | Health Technology |
Egenix, Inc.
Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Health Technology |
